{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:25:35Z","timestamp":1778253935116,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":330,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020\u00a0J011294"],"award-info":[{"award-number":["2020\u00a0J011294"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In B cells, the chemokine receptor CXCR3 is expressed only by a subset of B cells. However, CXCR3 is highly expressed in a rare type of B-cell lymphoma known as Mantle Cell Lymphoma (MCL) and CXCR3 inhibitor impairs proliferation and induces apoptosis in the MCL cell line JeKo-1. Despite this, the mechanism responsible for maintaining high levels of CXCR3 in MCL cells remains unclear. In this study, we assessed CXCR3 expression and amplification in MCL samples and confirmed that CXCR3 is overexpressed in MCL tissues. We also observed that CXCR3 amplification is present in a small portion of MCL patients and is associated with MCL classification. We then screened ubiquitin-specific proteases (USPs) that might control the degradation of CXCR3 protein. Our investigation revealed that USP35 acts as a potent stabilizer of CXCR3 protein. Knockdown of USP35 substantially reduced the CXCR3 protein levels in JeKo-1 cells, resulting in reduced cell viability, cell cycle arrest, increased apoptosis, and mitigated migration and invasion in these cells. At the molecular level, USP35 deubiquitinates and stabilizes CXCR3. USP35 deficiency attenuated the activation of the JAK1\/STAT1 pathway and reduced the expression of \u03b2-catenin and c-Myc in JeKo-1 cells. Furthermore, we observed that overexpression of CXCR3 rescued the impaired tumorigenicity of USP35-deficient JeKo-1 cells, and the mechanism may be related to the fact that USP35 promotes CXCR3 deubiquitination to stabilize its expression. These findings collectively demonstrate the oncogenic role of the USP35-CXCR3 axis in JeKo-1 MCL cells.<\/jats:p>","DOI":"10.1093\/intbio\/zyae021","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T22:32:37Z","timestamp":1732660357000},"source":"Crossref","is-referenced-by-count":4,"title":["The USP35-CXCR3 Axis plays an oncogenic role in JeKo-1 mantle cell lymphoma cells"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5716-6667","authenticated-orcid":false,"given":"Zongkai","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Pathology, Zhangzhou Affiliated Hospital of Fujian Medical University , No. 59, Shengli West Road, Xiangcheng District, Zhangzhou 363000, Fujian ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Basic Medicine, Zhangzhou Health Vocational College; Collaborative Innovation Center for Translation Medical Testing and Application Technology , No. 29, Shengli West Road, Xiangcheng District, Zhangzhou 363000, Fujian ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghe","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zhangzhou Affiliated Hospital of Fujian Medical University , No. 59, Shengli West Road, Xiangcheng District, Zhangzhou 363000, Fujian ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siling","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zhangzhou Affiliated Hospital of Fujian Medical University , No. 59, Shengli West Road, Xiangcheng District, Zhangzhou 363000, Fujian ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"2024112622322815500_ref1","article-title":"Mantle cell lymphoma","volume-title":"Stat Pearls [Internet]","author":"Lynch","year":"2023"},{"key":"2024112622322815500_ref2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"key":"2024112622322815500_ref3","doi-asserted-by":"crossref","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"key":"2024112622322815500_ref4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"key":"2024112622322815500_ref5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bjh.18597","article-title":"Survival of patients with mantle cell lymphoma in the rituximab era: retrospective binational analysis between 2000 and 2020","volume":"201","author":"Harmanen","year":"2023","journal-title":"Br J Haematol"},{"key":"2024112622322815500_ref6","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"2024112622322815500_ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092053","article-title":"The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities","volume":"13","author":"Neophytou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024112622322815500_ref8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"2024112622322815500_ref9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10753-020-01235-8","article-title":"The complexity of targeting chemokines to promote a tumor immune response","volume":"43","author":"Strazza","year":"2020","journal-title":"Inflammation"},{"key":"2024112622322815500_ref10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"2024112622322815500_ref11","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"Kurtova","year":"2009","journal-title":"Blood"},{"key":"2024112622322815500_ref12","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-21-3284","article-title":"Targeting refractory mantle cell lymphoma for imaging and therapy using C-X-C chemokine receptor type 4 Radioligands","volume":"28","author":"Kwon","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024112622322815500_ref13","doi-asserted-by":"crossref","first-page":"112365","DOI":"10.1016\/j.yexcr.2020.112365","article-title":"Expression and role of MIG\/CXCR3 axis in mantle cell lymphoma","volume":"397","author":"Zhu","year":"2020","journal-title":"Exp Cell Res"},{"key":"2024112622322815500_ref14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beha.2012.04.007","article-title":"Proteasome inhibitors in mantle cell lymphoma","volume":"25","author":"Holkova","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"2024112622322815500_ref15","first-page":"S21","article-title":"Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II","volume":"2","author":"O'Connor","year":"2004","journal-title":"J Natl Compr Canc Netw"},{"key":"2024112622322815500_ref16","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/onc.2011.443","article-title":"Deubiquitinases in cancer: new functions and therapeutic options","volume":"31","author":"Fraile","year":"2012","journal-title":"Oncogene"},{"key":"2024112622322815500_ref17","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1021\/acs.jmedchem.9b01138","article-title":"Advances in discovering deubiquitinating enzyme (DUB) inhibitors","volume":"63","author":"Schauer","year":"2020","journal-title":"J Med Chem"},{"key":"2024112622322815500_ref18","doi-asserted-by":"crossref","first-page":"101077","DOI":"10.1016\/j.jbc.2021.101077","article-title":"Deubiquitinating enzymes (DUBs): regulation, homeostasis, and oxidative stress response","volume":"297","author":"Snyder","year":"2021","journal-title":"J Biol Chem"},{"key":"2024112622322815500_ref19","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3389\/fphar.2018.01080","article-title":"Inhibition of ubiquitin-specific proteases as a novel anticancer therapeutic strategy","volume":"9","author":"Yuan","year":"2018","journal-title":"Front Pharmacol"},{"key":"2024112622322815500_ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090848","article-title":"Ubiquitin-specific proteases: players in cancer cellular processes","volume":"14","author":"Cruz","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024112622322815500_ref21","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2024112622322815500_ref22","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1046\/j.1365-2141.1998.00911.x","article-title":"Establishment and characterization of a mantle cell lymphoma cell line","volume":"102","author":"Jeon","year":"1998","journal-title":"Br J Haematol"},{"key":"2024112622322815500_ref23","doi-asserted-by":"publisher","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects","volume":"8","author":"Nguyen","year":"2017","journal-title":"Genes (Basel)"},{"key":"2024112622322815500_ref24","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/blood-2008-02-139212","article-title":"Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma","volume":"112","author":"Gelebart","year":"2008","journal-title":"Blood"},{"key":"2024112622322815500_ref25","doi-asserted-by":"crossref","first-page":"1022688","DOI":"10.3389\/fonc.2022.1022688","article-title":"The role of CXCR3 and its ligands in cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2024112622322815500_ref26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-030-36667-4_5","article-title":"The multifaceted roles of CXCL9 within the tumor microenvironment","volume":"1231","author":"Neo","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2024112622322815500_ref27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3892\/ol.2011.300","article-title":"The emerging role of CXCL10 in cancer (review)","volume":"2","author":"Liu","year":"2011","journal-title":"Oncol Lett"},{"key":"2024112622322815500_ref28","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2004-08-2992","article-title":"Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells","volume":"105","author":"Muehlinghaus","year":"2005","journal-title":"Blood"},{"key":"2024112622322815500_ref29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2050-7771-1-13","article-title":"The resistance mechanisms of proteasome inhibitor bortezomib","volume":"1","author":"Lu","year":"2013","journal-title":"Biomark Res"},{"key":"2024112622322815500_ref30","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5561","article-title":"USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination-mediated degradation","volume":"63","author":"Lv","year":"2023","journal-title":"Int J Oncol"},{"key":"2024112622322815500_ref31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41389-023-00458-2","article-title":"USP35 promotes cell proliferation and chemotherapeutic resistance through stabilizing FUCA1 in colorectal cancer","volume":"12","author":"Xiao","year":"2023","journal-title":"Oncogenesis"}],"container-title":["Integrative Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ib\/article-pdf\/doi\/10.1093\/intbio\/zyae021\/60818180\/zyae021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ib\/article-pdf\/doi\/10.1093\/intbio\/zyae021\/60818180\/zyae021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T22:32:44Z","timestamp":1732660364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ib\/article\/doi\/10.1093\/intbio\/zyae021\/7908925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1093\/intbio\/zyae021","relation":{},"ISSN":["1757-9708"],"issn-type":[{"value":"1757-9708","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024]]},"article-number":"zyae021"}}